Shiva Bolourchi: Marengo Therapeutics is proud to be disclosing new data at AACR describing the innovative expansion of our portfolio
Ke Liu, Chief Development Officer at Marengo Therapeutics, shared a post by , Head of Corporate Development and Strategy at Marengo Therapeutics on LinkedIn, adding:
“Congratulations to our Marengo research team for a great job done on the first disclosure of our novel V beta chain T cell engager platform – TriSTAR! So wonderful to discuss with colleagues here at AACR our novel technology that has great potential to transform the lives of people with cancer! Go Marengo Therapeutics!”
Quoting
“Marengo Therapeutics is proud to be disclosing new data at AACR describing the innovative expansion of our portfolio. We appreciate all the interest and great traffic at our poster. If you are here don’t miss out come check it out section 38!”
Source: Ke Liu/LinkedIn and Shiva Bolourchi/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023